Focal Interest
Focal Interest

Breast cancer

  1. Talazoparib resistance in triple-negative breast cancer linked to BRN2 and SHLD2
    Study identifies BRN2-mediated and SHLD2-related resistance to talazoparib in BRCA-mutant breast cancer, proposing combination therapy approaches to improve neoadjuvant treatment outcomes.
  2. Robotic process automation improved cancer registry abstraction efficiency
    RPA implementation for cancer registry data abstraction achieved 74% time reduction in gastric cancer and 30% in breast cancer, with success dependent on clinician cooperation and output monitoring.